Clinical value of including the head and lower extremities in F-FDG PET/CT imaging for patients with malignant melanoma

Nuclear Medicine Communications

Volumn 28, Issue 9, 2007, Pages 688-695

  Niederkohr, Ryan D ^a   Rosenberg, Jarrett ^a   Shabo, Gregory ^b   Quon, Andrew ^b  

^a Division of Nuclear Medicine   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Melanoma; Metastases; Oncology; PET; PET CT

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; BRAIN; CANCER DIAGNOSIS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; LEG; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; PATHOLOGY; RETROSPECTIVE STUDY; SCALP; SKULL; STATISTICAL SIGNIFICANCE;

ADULT; AGED; BRAIN NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HEAD; HUMANS; LEG; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; POSITRON-EMISSION TOMOGRAPHY; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 34547687433     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0b013e32827420cc     Document Type: Article

References (13)

1. Cancer Facts and Figures 2006. Atlanta: American Cancer Society. Available at (Accessed 20 September 2006).
2. Miller AJ, Mihm MC. Melanoma. N Engl J Med 2006; 355:51-65.
3. Belhocine TZ, Scott AM, Even-Sapir E, Urbain JL, Essner R. Role of nuclear medicine in the management of cutaneous malignant melanoma. J Nucl Med 2006; 47:957-967.
4. 18F-FDG PET/CT Imaging for N- and M-staging of malignant melanoma: Experience with 250 consecutive patients. J Clin Oncol 2006; 24:1178-1187.
5. Harris MT, Berlangieri SU, Cebon JS, Davis ID, Scott AM. Impact of 2-deoxy-2[F-18]fluoro-D-glucose positron emission tomography on the management of patients with advanced melanoma. Mol Imaging Biol 2005; 23:1-5.
6. Coleman RE, Delbeke D, Guiberteau MJ, et al. Concurrent PET/CT with an integrated imaging system: intersociety dialogue from the Joint Working Group of the American College of Radiology, the Society of Nuclear Medicine, and the Society of Computed Body Tomography and Magnetic Resonance. J Nucl Med 2005; 46:1225-1239.
7. Melanoma, version 2.2007. Clinical practice guidelines in oncology. National Comprehensive Cancer Network. Available at (Accessed 19 March 2007).
8. Swetter SM, Carroll LA, Johnson DL, Segall GM. Positron emission tomography is superior to computed tomography for metastatic detection in melanoma patients. Ann Surg Oncol 2002; 9:646-653.
9. 18F-fluorodeoxyglucose positron emission tomography/computed tomography and whole-body magnetic resonance imaging in staging of advanced malignant melanoma. Eur J Cancer 2007; 43:557-564.
10. Meier F, Will S, Ellwanger U, et al. Metastatic pathways and time courses in the orderly progression of cutaneous melanoma. Br J Dermatol 2002; 147:62-70.
11. Leiter U, Meier F, Schittek B, Garbe C. The natural course of cutaneous melanoma. J Surg Oncol 2004; 86:172-178.
12. Löffler M, Weckesser M, Franzius C, Nashan D, Schober O. Malignant melanoma and (18)F-FDG-PET: Should the whole body scan include the legs? Nuklearmedizin 2003; 42:167-172.
13. Crosby T, Fish R, Coles B, Mason MD. Systemic treatments for metastatic cutaneous melanoma. Cochrane Database Syst Rev 2000; CD001215.